Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Multiple Myeloma 68Recurrence 10Lymphoma 7Neoplasms, Plasma Cell 5Waldenstrom Macroglobulinemia 4Small Cell Lung Carcinoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell, Peripheral 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Leukemia 3Hematologic Neoplasms 3Ovarian Neoplasms 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Kidney Neoplasms 2Disease 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Salivary Gland Adenoma, Pleomorphic 1Renal Insufficiency 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Prolymphocytic 1

Interventions

Everolimus 6pasireotide 5Octreotide 5lanreotide 2ganitumab 2cabozantinib 2Bevacizumab 2surufatinib 1nintedanib 1ibrutinib 1gallium Ga 68 dotatate 1fosbretabulin 1epothilone B 1conatumumab 1cixutumumab 1carfilzomib 1azaspirane 1arginyllysine 1aflibercept 1Temozolomide 1TKM-080301 1Sunitinib 1Sorafenib 1Somatostatin 1Random Allocation 1Ramucirumab 1Quality of Life 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoid Tumor × carfilzomib × Clear all
NCT02318784 2023-12-05

Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

SCRI Development Innovations, LLC

Phase 2 Completed
62 enrolled 10 charts
Endocrine

Carcinoid Tumor, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡